Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/118990
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pérez-Olmeda, Mayte | - |
dc.contributor.author | Soriano, Vincent | - |
dc.contributor.author | Asensi, Victor | - |
dc.contributor.author | Morales, Dolores | - |
dc.contributor.author | Romero, Miriam | - |
dc.contributor.author | Ochoa, Anna | - |
dc.contributor.author | Sánchez-Montero, Fausto | - |
dc.contributor.author | Santín Cerezales, Miguel | - |
dc.contributor.author | Guardiola, Josep | - |
dc.contributor.author | Blanch, Jesús | - |
dc.contributor.author | Núñez, Marina | - |
dc.contributor.author | Jiménez-Nácher, Inmaculada | - |
dc.contributor.author | García-Samaniego, Javier | - |
dc.contributor.author | HCV/HIV Spanish Study Team | - |
dc.date.accessioned | 2018-01-11T12:26:52Z | - |
dc.date.available | 2018-01-11T12:26:52Z | - |
dc.date.issued | 2003-12 | - |
dc.identifier.issn | 0889-2229 | - |
dc.identifier.uri | http://hdl.handle.net/2445/118990 | - |
dc.description.abstract | One hundred six HIV-infected patients with chronic hepatitis C virus (HCV) infection were randomized to receive ribavirin (RBV) 400 mg bid plus interferon α-2b (IFN-α) at two different doses, 3 mU tiw (control arm) or 5 mU daily for the first 6 weeks, followed by 3 mU tiw until completing 6 months of therapy (induction arm). All patients had CD4 counts above 350 cells/μl and 89% were taking antiretroviral therapy. Adverse effects leading to treatment discontinuation occurred in 12.3% of patients, a rate quite similar to that seen in HCV-monoinfected patients. Negative serum HCV-RNA values (<60 IU/ml) were recorded in 24.7% and 35.5% of patients at 3 and 6 months of therapy. However, in the intent-to-treat analysis, sustained response was reached by only 16% of patients (22.4% in the on-treatment analysis). No differences between treatment arms were noticed. Patients with HCV genotypes 2 or 3 had a 7-fold higher response rate than those with HCV genotypes 1 or 4. Therefore, early, end-of-treatment, and sustained response rates are lower in HIV/HCV-coinfected patients treated with RBV/IFN-α combination therapy. Since HCV-related liver disease is currently one of the leading causes of morbidity and mortality among HIV-infected patients, new treatment options are urgently needed for coinfected individuals. | - |
dc.format.extent | 7 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Mary Ann Liebert | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1089/088922203771881176 | - |
dc.relation.ispartof | Aids Research and Human Retroviruses, 2003, vol. 19, num. 12, p. 1083-1089 | - |
dc.relation.uri | https://doi.org/10.1089/088922203771881176 | - |
dc.rights | (c) Mary Ann Liebert, 2003 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Hepatitis C | - |
dc.subject.classification | Interferó | - |
dc.subject.classification | Efecte dels medicaments sobre els microorganismes | - |
dc.subject.classification | Medicaments antivírics | - |
dc.subject.classification | Infeccions per VIH | - |
dc.subject.other | Hepatitis C | - |
dc.subject.other | Interferon | - |
dc.subject.other | Effect of drugs on microorganisms | - |
dc.subject.other | Antiviral agents | - |
dc.subject.other | HIV infections | - |
dc.title | Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α-2b Plus Ribavirin | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 654015 | - |
dc.date.updated | 2018-01-11T12:26:52Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 14709244 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
654015.pdf | 162.98 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.